Key result
Dipyridamole specifically decreased platelet-derived growth factor (PDGF) release from platelets, an effect not seen with aspirin, trapidil, or ticlopidine.
Why the study?
Does dipyridamole specifically decrease PDGF release from platelets compared to other anti-platelet drugs?
Does dipyridamole specifically decrease PDGF release from platelets compared to other anti-platelet drugs?
Dipyridamole specifically inhibits the release of PDGF from platelets without affecting other alpha-granule factors, suggesting potential utility in preventing PDGF-related disorders.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dipyridamole in PDGF-mediated disorders; human trials required before any clinical consideration.
We previously reported that dipyridamole decreased platelet-derived growth factor (PDGF) levels in human serum by lowering the release of PDGF during blood clotting. In this study, we have shown that this effect is specific for dipyridamole, and is not shown in other anti-platelet drugs such as aspirin, trapidil or ticlopidine. In addition, dipyridamole has been shown to decrease the PDGF level selectively, but not the levels of other factors from alpha-granules in platelets (beta-thromboglobulin and platelet factor IV). These data indicate that dipyridamole may be an effective drug for preventing PDGF-related disorders.
No takes yet. Share an insight, caveat, or question.
Takehara et al. (2008) studied this question. Dipyridamole vs. Aspirin, trapidil, or ticlopidine was evaluated on Platelet-derived growth factor (PDGF) release from platelets. Dipyridamole specifically decreased platelet-derived growth factor (PDGF) release from platelets, an effect not seen with aspirin, trapidil, or ticlopidine.
Synapse has enriched 10 related papers. Consider them for comparative context: